Evidence to move therapy earlier in melanoma

Targeted therapies and immunotherapies have an earlier role to play in the management of melanoma, according to interim findings from two international studies in predominantly stage III resected disease. The findings, presented this week at the European Society for Medical Oncology (ESMO) Annual Congress, suggest patients should not have to wait for recurrence before accessing ...

Already a member?

Login to keep reading.

© 2022 the limbic